IDYA

Ideaya Biosciences Inc

36.58

Oct 23 • 6:01 AM ET +0.46 (1.28%)

Healthcare Biotechnology USA Mid NASD

Peers: IMCR TNGX AURA REPL RLAY ERAS PBLS RVMD CELC IOVA

| Held by: VTI IWM XBI VXF IWN IBB DFAS VTWO SCHA DFAC

Index	RUT
Market Cap	3.53B
Enterprise Value	2.73B
Income	-175.02M
Sales	234.13M
Book/sh	12.44
Cash/sh	8.59
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	145
IPO	May 23, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	15.08
P/B	2.94
P/C	4.26
P/FCF	-
EV/EBITDA	-
EV/Sales	11.66
Quick Ratio	10.45
Current Ratio	10.45
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.94
EPS next Y	-4.23
EPS next Q	-1.17
EPS this Y	-259.77%
EPS next Y	8.25%
EPS next 5Y	-
EPS past 3/5Y	3.17% 1.64%
Sales past 3/5Y	62.54% 62.11%
EPS Y/Y TTM	49.14%
Sales Y/Y TTM	3244.67%
EPS Q/Q	-39.46%
Sales Q/Q	-
Earnings	Aug 04 BMO
EPS/Sales Surpr.	-15.46% 10.44%

Insider Own	6.64%
Insider Trans	-0.56%
Inst Own	101.97%
Inst Trans	6.77%
ROA	-14.89%
ROE	-16.22%
ROIC	-14.26%
Gross Margin	98.08%
Oper. Margin	-92.66%
Profit Margin	-74.75%
SMA20	1.48%
SMA50	-3.10%
SMA200	7.24%
Trades

Shs Outstand	96.38M
Shs Float	90.08M
Short Float	10.19%
Short Ratio	11.62
Short Interest	9.18M
52W High	42.68 -14.29%
52W Low	26.81 36.45%
Volatility	3.80% 4.00%
ATR (14)	1.29
RSI (14)	52.08
Beta	0.06
Rel Volume	0.00
Avg Volume	790.12K
Volume	74

Perf Week	11.36%
Perf Month	-0.43%
Perf Quarter	-0.51%
Perf Half Y	19.05%
Perf YTD	5.82%
Perf Year	28.72%
Perf 3Y	37.07%
Perf 5Y	59.61%
Perf 10Y	-
Recom	1.12
Target Price	52.38
Prev Close	36.12
Price	36.58
Change %	1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-26	Initiated	William Blair	Outperform
Oct-14-26	Resumed	Stifel	Buy	$48
Jan-07-26	Resumed	UBS	Buy	$50
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Guggenheim	Buy	$50
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform	$41
Sep-04-25	Initiated	Barclays	Overweight	$40
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral	$25
Jun-26-25	Initiated	Wells Fargo	Overweight	$44
Nov-18-24	Initiated	Stephens	Overweight	$51
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27
Oct-24-24	Initiated	UBS	Buy	$50
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26

Show Previous Ratings

Today 06:00AM	IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas (PR Newswire)
Oct-19-26 06:00AM	IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma (PR Newswire)
Sep-28-26 06:00AM	IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development (PR Newswire)
Sep-25-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-09-26 06:00AM	IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma (PR Newswire)
06:00AM	Loading…
Sep-01-26 06:00AM	IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences (PR Newswire)
Aug-31-26 06:00AM	IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer (PR Newswire)
Aug-28-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-19-26 06:00AM	IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer (PR Newswire)
Aug-04-26 06:00AM	IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Jul-31-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-27-26 06:00AM	IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers (PR Newswire)
Jul-17-26 09:00AM	IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs (PR Newswire)
Jun-26-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-17-26 06:00AM	IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors (PR Newswire)
06:00AM	Loading…
Jun-15-26 06:00AM	IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers (PR Newswire)
Jun-10-26 04:05PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-08-26 10:22PM	IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.28% -10.83%
04:01PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
Jun-03-26 06:00AM	IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer (PR Newswire)
Jun-01-26 11:00AM	IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO (PR Newswire)
May-29-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-26 06:00AM	IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire)
May-05-26 06:00AM	IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Apr-30-26 06:00AM	IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program (PR Newswire)
Apr-21-26 10:15AM	IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire) -5.27%
Apr-14-26 04:55AM	Novo teams with OpenAI; Ideaya gets muted response to eye drug data (BioPharma Dive)
Apr-13-26 10:55AM	Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma (Investor's Business Daily) +7.61%
07:21AM	Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results (Barrons.com)
06:00AM	Loading…
06:00AM	These Stocks Are Today's Movers: Goldman Sachs, Sandisk, Exxon Mobil, Nvidia, Ideaya, and More (Barrons.com)
06:00AM	IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma (PR Newswire)
Apr-10-26 04:05PM	IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 (PR Newswire)
Apr-06-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer (PR Newswire)
Mar-30-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma (PR Newswire)
Mar-27-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.08%
Mar-22-26 10:00AM	IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial (PR Newswire)
Mar-18-26 06:00AM	IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PR Newswire)
Mar-09-26 09:10AM	DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier (Zacks) +5.69%
06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update (PR Newswire)
Mar-06-26 10:22AM	IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC (Insider Monkey)
Feb-27-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-25-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC (PR Newswire)
Feb-23-26 02:28PM	IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch (MarketBeat)
01:13PM	IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit (MarketBeat)
06:00AM	IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer (PR Newswire)
Feb-17-26 06:00AM	IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (PR Newswire)
Feb-02-26 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events (PR Newswire) +5.81%
Jan-30-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-26 09:21AM	Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? (Zacks)
Jan-11-26 12:00PM	IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-05-26 06:00AM	IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-11-25 06:00AM	IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-10-25 06:00AM	IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers (PR Newswire)
Dec-04-25 07:00PM	IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance (Business Wire)
Dec-01-25 06:00AM	IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types (PR Newswire)
Nov-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-24-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events (PR Newswire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
Nov-04-25 06:00AM	IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Oct-31-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-27-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events (PR Newswire) +10.93%
Oct-20-25 06:30AM	IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 (PR Newswire)
06:00AM	IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
Oct-17-25 09:55PM	Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey) +5.67%
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-08-25 12:57AM	J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey)
Sep-26-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-10-25 12:59AM	Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating (Insider Monkey)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) -13.88%
08:00AM	IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy in MTAP-Deletion Urothelial Cancer (PR Newswire)
06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma (PR Newswire)
Sep-07-25 12:00PM	IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer (PR Newswire)
Sep-04-25 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy in MTAP-Deletion Non-Small Cell Lung Cancer (PR Newswire)
Sep-03-25 06:00AM	IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PR Newswire)
Sep-02-25 06:00AM	Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide (PR Newswire)
Aug-29-25 02:00PM	IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-25-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events (PR Newswire)
Aug-18-25 06:00AM	IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 (PR Newswire)
Aug-05-25 06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-01-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-24-25 11:47PM	TD Cowen Bullish on Ideaya's (IDYA) Oncology Pipeline (Insider Monkey) +5.08%
09:25AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma (PR Newswire)
Jul-23-25 06:00AM	IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy (PR Newswire) +7.31%
Jul-22-25 01:01PM	IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC (PR Newswire)
Jul-21-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event (PR Newswire)
Jun-27-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-02-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire) +6.69%
May-30-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-06-25 06:05AM	IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -13.29%
06:00AM	IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors (PR Newswire)
May-05-25 07:51AM	Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-28-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events (PR Newswire)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-25-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-16-25 08:52AM	Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later (Seeking Alpha)
Apr-14-25 06:00AM	IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire)
Apr-10-25 06:00AM	IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hata Yujiro S	President and CEO	Oct 06 '26	Option Exercise	4.31	26,338	113,517	717,033	Oct 08 07:03 PM
Hata Yujiro S	President and CEO	Oct 06 '26	Sale	37.41	26,338	985,397	690,695	Oct 08 07:03 PM
YUJIRO HATA	CEO	Oct 06 '26	Proposed Sale	38.23	230,316	8,804,981		Oct 06 04:13 PM
Ruiz Briseno Andres	Chief Accounting Officer	Jul 07 '26	Option Exercise	12.86	9,550	122,813	36,016	Jul 09 04:56 PM
Ruiz Briseno Andres	Chief Accounting Officer	Jul 07 '26	Sale	40.01	9,550	382,131	26,466	Jul 09 04:56 PM
Andres Ruiz Briseno	Senior VP	Jul 07 '26	Proposed Sale	40.01	9,550	382,131		Jul 07 04:54 PM
Stein Jeffrey	Director	Mar 02 '26	Buy	32.96	50,000	1,647,890	54,281	Mar 02 07:18 PM

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

FounderMr. Yujiro S. Hata

Ph.D.Dr. Joshua Bleharski M.B.A.

Chief Accounting OfficerMr. Andres Ruiz Briseno CPA

Chief Legal OfficerMr. Douglas B. Snyder

President of Research & DevelopmentDr. Michael A. White Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your Finviz experience